MK 3577 is an orally active glucagon receptor antagonist which was under development by Merck & Co for the treatment of type 2 diabetes mellitus. MK 3577 demonstrate activity in cellular models and preclinical trials. In phase II clinical trials MK 3577 shows good efficacy and acceptable level of adverse events, but no further development reports were published.

MK-1064 is an orexin 2 receptor antagonist patented by pharmaceutical company Merck & Co for the treatment of insomnia. MK-1064decreases the amount of time spent in active wake and increases the time spent in rapid eye movement (REM) sleep and slow-wave sleep (SMS) in mice, rats, dogs, and rhesus monkeys. MK-1064, even at the very high dose did not show signs of an enhanced predisposition to cataplexy in the food-elicited cataplexy test. MK-1064 has now completed two Phase I studies focused on pharmacokinetics, safety and sleep in healthy volunteers. The effects of MK-1064 on sleep parameters were moderate, but statistically significant, representing the first demonstration of PSG-quantified sleep induced in humans by an OX2R antagonist. MK-1064 at 50, 120 and 250 mg decreased latency to persistent sleep and wake after sleep onset, and increased total sleep time and sleep efficiency.

Bristol-Myers Squibb developed BMS-929075 as a selective, orally bioavailable hepatitis C virus (HCV) NS5B polymerase inhibitor for the treatment of chronic HCV infection. BMS-929075 was involved in phase I clinical trials for hepatitis C virus (HCV) infected patients; however, the company withdrew a study prior to enrolment.

MK-6325 is a potent HCV NS3/4A protease inhibitor patented by Merck Sharp & Dohme Corp for treating or preventing HCV infections. In 2011 MK-6325 was studied in phase I clinical trials but no further development reports were published.

TBA-354, also known as SN31354, is a potent anti-tuberculosis drug candidate. TBA-354 is narrow spectrum and bactericidal in vitro against replicating and nonreplicating Mycobacterium tuberculosis, with potency similar to that of delamanid and greater than that of PA-824. TBA-354 maintains activity against Mycobacterium tuberculosis H37Rv isogenic monoresistant strains and clinical drug-sensitive and drug-resistant isolates. TBA-354 is a promising next-generation nitroimidazole antitubercular agent. TBA-354 emerged from studies designed to identify a next generation nitroimidazole for TB. TB Alliance conducted the studies in collaboration with the University of Auckland and University of Illinois-Chicago. Once identified, TB Alliance further advanced TBA-354 through pre-clinical development and is now the sponsor of the Phase 1 study.

(+)-Epicatechin or ent-Epicatechin is one of the 4 catechin diastereoisomers. (+)-Epicatechin has been isolated from various species of Palmae. It is occurred in the leaves or fruit of six palm species. In addition, it was isolated from Dryas octopetala and guarana seeds. It resists to the microbial transformation by endophytic fungi isolated from a tea plant.